The Interaction between the Bone Marrow Microenvironment and Immunotherapy in Multiple Myeloma: Mechanisms, Challenges, and Prospects
Year: 2025
Type: article
Abstract: 现阶段多发性骨髓瘤仍是一种无法治愈的疾病。近年来，以CD38单克隆抗体为代表的免疫治疗药物在临床中的应用显著延长了MM患者的生存时间。同时嵌合抗原受体(CAR-T细胞)和双特异性抗体(BsAbs)等新型免疫治疗手段的不断发展，正在逐步改变MM的治疗格局。然而免疫治疗在MM中的应用仍面临诸多挑战，例如肿瘤细胞的高度异质性、骨髓微环境的免疫抑制以及代谢相关障碍等问题。未来的研究和治疗策略需要进一步优化，通过联合靶向骨髓微环境和免疫调节，提升免疫治疗的疗效和安全性，从而为骨髓瘤患者争取更好的预后。Multiple myeloma (MM) remains an incurable disease. In recent years, the clinical application of immune therapies, particularly CD38 monoclonal antibodies, has significantly extended the survival of MM patients. Additionally, the emergence of innovative immunotherapies, such as chimeric antigen receptor (CAR-T) cells and bispecific antibodies (BsAbs), is reshaping the treatment paradigm of MM. However, significant challenges persist in the application of immunotherapy for MM, including tumor heterogeneity, the immunosuppressive bone marrow microenvironment, and metabolic dysregulation. Moving forward, optimizing treatment strategies that integrate targeting of the bone marrow microenvironment with immune modulation may further enhance the efficacy and safety of immunotherapies, ultimately improving outcomes for MM patients.
Source: Advances in Clinical Medicine
Author: 慧敏 张
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W4409302032